Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Authors:

Abstract
Key Points: In adults undergoing allo-HSCT, vedolizumab IV 300 mg was well tolerated and had a low incidence of overall and lower-intestinal aGVHD. These phase 1b data support further evaluation of vedolizumab for the prevention of aGVHD in adults undergoing allo-HSCT.

This publication has 35 references indexed in Scilit: